Literature DB >> 31696627

Myocardial adipose deposition and the development of heart failure with preserved ejection fraction.

Cho-Kai Wu1, Jen-Kuang Lee1, Jung-Chi Hsu2, Mao-Yuan M Su3, Yi-Fan Wu4, Ting-Tse Lin5,6, Chen-Wei Lan7, Juey-Jen Hwang1, Lian-Yu Lin1.   

Abstract

AIMS: It has been proposed that an increase of myocardial adiposity is related to left ventricular (LV) diastolic dysfunction. The specific roles of myocardial steatosis including epicardial fat and intramyocardial fat for diastolic function are unknown in those patients suffering heart failure (HF) with reduced (HFrEF) or preserved ejection fraction (HFpEF). This study aims to determine the complex relationship between myocardial adiposity in patients with HFrEF or HFpEF. METHODS AND
RESULTS: Using cardiac magnetic resonance imaging (CMRI), myocardial steatosis was measured in 305 subjects (34 patients with HFrEF, 163 with HFpEF, and 108 non-HF controls). We also evaluated cardiac structure and diastolic and systolic function by echocardiography and CMRI. Patients with HFpEF had significantly more intramyocardial fat than HFrEF patients or non-HF controls [intramyocardial fat content (%), 1.56 (1.26, 1.89) vs. 0.75 (0.50, 0.87) and 1.0 (0.79, 1.15), P < 0.05]. Intramyocardial fat amount (%) was higher in HFpEF women than in men [1.91% (1.17%, 2.32%) vs. 1.22 (0.87%, 2.02%), P = 0.01]. When estimated by CMRI (left ventricular peak filling rate), echocardiographic E/e' level, or left atrial volume index, intramyocardial fat correlated with LV diastolic dysfunction parameters in HFpEF patients, and this was independent of age, co-morbidities, body mass index, gender, and myocardial fibrosis (standardized coefficient: β = -0.34, P = 0.03; β = 0.29, P = 0.025; and β = 0.25, P = 0.02, respectively).
CONCLUSIONS: Patients with HFpEF had significantly more intramyocardial fat than HFrEF patients or non-HF controls. Independent of risk factors or gender, intramyocardial fat correlated with LV diastolic dysfunction parameters in HFpEF patients.
© 2019 European Society of Cardiology.

Entities:  

Keywords:  Cardiac magnetic resonance imaging; Diastolic dysfunction; Heart failure; Myocardial steatosis; Women

Mesh:

Year:  2019        PMID: 31696627     DOI: 10.1002/ejhf.1617

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  16 in total

1.  Texture analysis of native T1 images as a novel method for non-invasive assessment of heart failure with preserved ejection fraction in end-stage renal disease patients.

Authors:  Tian-Yi Zhang; Dong-Aolei An; Hang Zhou; Zhaohui Ni; Qin Wang; Binghua Chen; Renhua Lu; Jiaying Huang; Yin Zhou; Doo Hee Kim; Molly Wilson; Lian-Ming Wu; Shan Mou
Journal:  Eur Radiol       Date:  2022-10-19       Impact factor: 7.034

Review 2.  Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease.

Authors:  Milton Packer; Carolyn S P Lam; Lars H Lund; Mathew S Maurer; Barry A Borlaug
Journal:  Eur J Heart Fail       Date:  2020-06-26       Impact factor: 15.534

3.  Association of Circulating Trimethylamine N-Oxide and Its Dietary Determinants with the Risk of Kidney Graft Failure: Results of the TransplantLines Cohort Study.

Authors:  Jose L Flores-Guerrero; Maryse C J Osté; Paula B Baraldi; Margery A Connelly; Erwin Garcia; Gerjan Navis; Stephan J L Bakker; Robin P F Dullaart
Journal:  Nutrients       Date:  2021-01-18       Impact factor: 5.717

Review 4.  Lipotoxicity: a driver of heart failure with preserved ejection fraction?

Authors:  Jennifer Leggat; Guillaume Bidault; Antonio Vidal-Puig
Journal:  Clin Sci (Lond)       Date:  2021-10-15       Impact factor: 6.876

5.  The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients.

Authors:  Gijs van Woerden; Dirk J van Veldhuisen; Thomas M Gorter; Bob Ophuis; Huitzilihuitl Saucedo-Orozco; Vanessa P M van Empel; Tineke P Willems; Bastiaan Geelhoed; Michiel Rienstra; Berend Daan Westenbrink
Journal:  ESC Heart Fail       Date:  2022-02-11

6.  Association of beta-hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort.

Authors:  Jose L Flores-Guerrero; Berend Daan Westenbrink; Margery A Connelly; James D Otvos; Dion Groothof; Irina Shalaurova; Erwin Garcia; Gerjan Navis; Rudolf A de Boer; Stephan J L Bakker; Robin P F Dullaart
Journal:  Eur J Clin Invest       Date:  2020-12-18       Impact factor: 4.686

Review 7.  Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier.

Authors:  Edgar E Nollet; B Daan Westenbrink; Rudolf A de Boer; Diederik W D Kuster; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-11-11       Impact factor: 6.106

8.  Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.

Authors:  Antje Schauer; Volker Adams; Antje Augstein; Anett Jannasch; Runa Draskowski; Virginia Kirchhoff; Keita Goto; Jeniffer Mittag; Roberta Galli; Anita Männel; Peggy Barthel; Axel Linke; Ephraim B Winzer
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

Review 9.  Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets.

Authors:  Paolo Severino; Andrea D'Amato; Silvia Prosperi; Francesca Fanisio; Lucia Ilaria Birtolo; Bettina Costi; Lucrezia Netti; Cristina Chimenti; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Int J Mol Sci       Date:  2021-07-17       Impact factor: 6.208

10.  Association of epicardial fat thickness with left ventricular diastolic function parameters in a community population.

Authors:  Wei Ma; Baowei Zhang; Ying Yang; Litong Qi; Jin Zhou; Min Li; Jia Jia; Yan Zhang; Huo Yong
Journal:  BMC Cardiovasc Disord       Date:  2021-05-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.